The primary objective of this phase IIb/III study is to evaluate whether the combinationof lurbinectedin plus doxorubicin given as first line treatment for metastaticleiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent ReviewCommittee (IRC) when compared to doxorubicin administered as a single agent.
The primary objective of this phase IIb/III study is to evaluate whether the combinationof lurbinectedin plus doxorubicin given as first line treatment for metastaticleiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent ReviewCommittee (IRC) when compared to doxorubicin administered as a single agent.
